HRP20040663B1 - Peptidi za lijeäśenje raka povezanog s humanim papiloma virusom (hpv) i drugih vrsta epitelnih tumora - Google Patents

Peptidi za lijeäśenje raka povezanog s humanim papiloma virusom (hpv) i drugih vrsta epitelnih tumora

Info

Publication number
HRP20040663B1
HRP20040663B1 HRP20040663AA HRP20040663A HRP20040663B1 HR P20040663 B1 HRP20040663 B1 HR P20040663B1 HR P20040663A A HRP20040663A A HR P20040663AA HR P20040663 A HRP20040663 A HR P20040663A HR P20040663 B1 HRP20040663 B1 HR P20040663B1
Authority
HR
Croatia
Prior art keywords
peptides
hpv
relates
treatment
ckii
Prior art date
Application number
HRP20040663AA
Other languages
English (en)
Inventor
Silvio Ernesto Perea Rodriguez
Osvaldo Reyes Acosta
Nelson Francisco Santiago Vispo
Yaquelin Puchades Izaguirre
Ricardo Silva Rodriguez
Alejandro Moro Soria
Alieia Santos Savio
Luis Javier Gonzalez Lopez
Original Assignee
Centro De Ingenieria Genetica Y Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Ingenieria Genetica Y Biotecnologia filed Critical Centro De Ingenieria Genetica Y Biotecnologia
Publication of HRP20040663A2 publication Critical patent/HRP20040663A2/hr
Publication of HRP20040663B1 publication Critical patent/HRP20040663B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Izum se odnosi na peptide koji se upotrebljavaju za liječenje epitelnih tumora, a posebno onih koji su povezani s onkogenim tipom papiloma virusa (HPV). Izum se također odnosi na identifikaciju peptida sa strukturom koja omogućuje blokiranje domene fosforilacije s kazein kinazom II (CKII) izravnom interakcijom s tim mjestom. Prema izumu se upotrebljava jedanaest peptida koji imaju cikličku strukturu i različite sekvence amino kiselina. Ti peptidi inhibiraju mjesto fosforilacije pomoću in vitro CKII; oni uzrokuju citotoksičnost u stanicama karcinoma u grliću humanog uterusa transformiranih s HPV-16 (CaSki) i oni povisuju osjetljivost tih stanica prema citostatičkom učinku interferona (IFN). Izum se također odnosi na upotrebu tih peptida konjugiranih ili fuzioniranih na druge peptide i kemijske spojeve koji prodiru u stanice. Osim toga, izum se odnosi i na upotrebu mimičkih molekula peptidnog i kemijskog porijekla.
HRP20040663AA 2001-12-20 2004-07-19 Peptidi za lijeäśenje raka povezanog s humanim papiloma virusom (hpv) i drugih vrsta epitelnih tumora HRP20040663B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20010309A CU23225A1 (es) 2001-12-20 2001-12-20 PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
PCT/CU2002/000010 WO2003054002A1 (es) 2001-12-20 2002-12-04 Péptidos para el tratamiento del cáncer asociado al virus papiloma humano (vph) y de otros tumores epiteliales

Publications (2)

Publication Number Publication Date
HRP20040663A2 HRP20040663A2 (en) 2005-08-31
HRP20040663B1 true HRP20040663B1 (hr) 2013-05-31

Family

ID=40091679

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040663AA HRP20040663B1 (hr) 2001-12-20 2004-07-19 Peptidi za lijeäśenje raka povezanog s humanim papiloma virusom (hpv) i drugih vrsta epitelnih tumora

Country Status (34)

Country Link
US (2) US7374767B2 (hr)
EP (2) EP2383282A1 (hr)
JP (1) JP4056476B2 (hr)
KR (1) KR100642437B1 (hr)
CN (1) CN100368431C (hr)
AR (1) AR037825A1 (hr)
AT (1) ATE520704T1 (hr)
AU (1) AU2002361922B2 (hr)
BR (1) BRPI0215213C1 (hr)
CA (1) CA2471110C (hr)
CR (1) CR7361A (hr)
CU (1) CU23225A1 (hr)
DK (1) DK1491553T3 (hr)
DO (1) DOP2002000548A (hr)
ES (1) ES2371239T3 (hr)
HK (1) HK1068901A1 (hr)
HN (1) HN2002000377A (hr)
HR (1) HRP20040663B1 (hr)
IL (2) IL162633A0 (hr)
IS (1) IS2906B (hr)
MA (1) MA27868A1 (hr)
MX (1) MXPA04005832A (hr)
MY (1) MY133530A (hr)
NO (1) NO333259B1 (hr)
NZ (1) NZ534170A (hr)
PE (1) PE20030861A1 (hr)
PT (1) PT1491553E (hr)
RU (1) RU2290410C2 (hr)
SI (1) SI1491553T1 (hr)
TN (1) TNSN04114A1 (hr)
UA (1) UA81403C2 (hr)
UY (1) UY27602A1 (hr)
WO (1) WO2003054002A1 (hr)
ZA (1) ZA200405514B (hr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
CU23431B6 (es) 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
GB2433740A (en) * 2005-12-23 2007-07-04 Rapid Biosensor Systems Ltd Detection of tuberculosis infection
CU23511B6 (es) 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
GB2441131A (en) * 2006-08-24 2008-02-27 Univ Dundee Modulation of binding of CK2a to NDPK
CN100522992C (zh) * 2007-02-12 2009-08-05 中国科学院昆明动物研究所 一种环状小肽ba
CN101641104B (zh) * 2007-03-27 2013-06-05 大幸药品株式会社 感染性皮肤和粘膜疾病治疗药
WO2010096751A1 (en) 2009-02-23 2010-08-26 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta
JP2012520085A (ja) * 2009-03-13 2012-09-06 エーゲン、インコーポレイテッド 生物活性ｒｎａの送達のための組成物及び方法
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
CU20200103A7 (es) * 2020-12-18 2022-07-08 Ct Ingenieria Genetica Biotecnologia Péptido sintético para la inducción de inmunidad antitumoral y antiviral
CU20210058A7 (es) 2021-07-09 2023-02-13 Ct Ingenieria Genetica Biotecnologia Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden
CN118370805A (zh) * 2024-04-29 2024-07-23 广州美达康生物医药科技有限公司 一种抑菌妇科凝胶及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412762A2 (en) * 1989-08-07 1991-02-13 Merck & Co. Inc. Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins
EP0531080A2 (en) * 1991-09-04 1993-03-10 Merck & Co. Inc. Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene protein
WO1995001374A1 (en) * 1993-07-01 1995-01-12 British Technology Group Limited Synthetic peptides of human papillomavirus
EP0666270A2 (en) * 1994-02-08 1995-08-09 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
EP0969013A1 (en) * 1998-06-30 2000-01-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides for inhibiting HPV E7 proteins
US20010029022A1 (en) * 1999-08-25 2001-10-11 Christopher Fisher Methods of identifying anti-viral agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412762A2 (en) * 1989-08-07 1991-02-13 Merck & Co. Inc. Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins
EP0531080A2 (en) * 1991-09-04 1993-03-10 Merck & Co. Inc. Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene protein
WO1995001374A1 (en) * 1993-07-01 1995-01-12 British Technology Group Limited Synthetic peptides of human papillomavirus
EP0666270A2 (en) * 1994-02-08 1995-08-09 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
EP0969013A1 (en) * 1998-06-30 2000-01-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides for inhibiting HPV E7 proteins
US20010029022A1 (en) * 1999-08-25 2001-10-11 Christopher Fisher Methods of identifying anti-viral agents

Also Published As

Publication number Publication date
MA27868A1 (fr) 2006-05-02
NZ534170A (en) 2006-08-31
UY27602A1 (es) 2003-04-30
IS7320A (is) 2004-06-16
CA2471110C (en) 2017-01-31
HRP20040663A2 (en) 2005-08-31
TNSN04114A1 (en) 2006-06-01
ZA200405514B (en) 2005-03-30
HN2002000377A (es) 2003-04-10
US7947287B2 (en) 2011-05-24
UA81403C2 (en) 2008-01-10
IL162633A (en) 2011-02-28
DK1491553T3 (da) 2011-12-05
IL162633A0 (hr) 2005-11-20
CA2471110A1 (en) 2003-07-03
BR0215213A (pt) 2004-12-07
CU23225A1 (es) 2007-08-30
BRPI0215213B1 (pt) 2018-09-11
CN100368431C (zh) 2008-02-13
CR7361A (es) 2005-02-18
PT1491553E (pt) 2011-11-25
AR037825A1 (es) 2004-12-09
BRPI0215213C1 (pt) 2021-05-25
HK1068901A1 (en) 2005-05-06
NO333259B1 (no) 2013-04-22
EP2383282A1 (en) 2011-11-02
EP1491553A1 (en) 2004-12-29
ES2371239T3 (es) 2011-12-28
US20090005294A1 (en) 2009-01-01
US20060233742A1 (en) 2006-10-19
JP4056476B2 (ja) 2008-03-05
SI1491553T1 (sl) 2011-12-30
KR20050002811A (ko) 2005-01-10
KR100642437B1 (ko) 2006-11-06
MY133530A (en) 2007-11-30
RU2004122084A (ru) 2005-03-27
RU2290410C2 (ru) 2006-12-27
AU2002361922B2 (en) 2007-04-05
MXPA04005832A (es) 2004-09-13
AU2002361922A1 (en) 2003-07-09
JP2005525090A (ja) 2005-08-25
IS2906B (is) 2014-11-15
WO2003054002A1 (es) 2003-07-03
EP1491553B1 (en) 2011-08-17
PE20030861A1 (es) 2003-12-02
CN1620464A (zh) 2005-05-25
DOP2002000548A (es) 2003-06-30
ATE520704T1 (de) 2011-09-15
NO20043112L (no) 2004-07-20
US7374767B2 (en) 2008-05-20

Similar Documents

Publication Publication Date Title
HRP20040663B1 (hr) Peptidi za lijeäśenje raka povezanog s humanim papiloma virusom (hpv) i drugih vrsta epitelnih tumora
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
DE69330988D1 (de) Peptide des menschlichen papillomavirus zur verwendung in zusammensetzungen, die eine menschliche t-zellreaktion induzieren
ES2058898T3 (es) Compuesto farmaceutico, util a titulo preventivo o curativo contra los tumores inducidos por los papilomavirus.
HUP0302334A2 (hu) Vírusellenes hatású nukleozid-vegyületek prekurzorjai, valamint e vegyületek alkalmazása gyógyászati készítmények előállítására
CY1105866T1 (el) Αναλογα ταμανταρινης και διδεμνινης και μεθοδοι παρασκευης και χρησης αυτων
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
CY1105746T1 (el) Eνωσεις που επηρεαζουν τη γλυκοκιναση
MXPA05007843A (es) Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
SG131116A1 (en) Functional influenza virus-like particles (vlps)
BRPI0406800B8 (pt) "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
ATE519500T1 (de) Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung
WO2018120277A1 (zh) 包含f1、f3多肽的药物组合物及其在治疗hpv感染疾病中的应用
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
BR0111393A (pt) Métodos de tratamento de doenças virais com il-18 e suas combinações
ATE356207T1 (de) Humanes btrcp protein
DE50002164D1 (de) Peptide zur inhibierung von hpv e6-proteinen
EA199900438A1 (ru) Препарат местного применения для введения пептидных лекарственных средств в живые организмы
KR920012114A (ko) 사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gaa)의 선택된 펩타이드, 이의 제법 및 용도
TH59183B (th) เพพไทด์สำหรับการรักษามะเร็งที่เกี่ยวข้องกับแพพิลโลมาไวรัส (hpv) ของมนุษย์และเนื้องอกของเนื้อเยื่อบุผิวอื่น
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
DE60018937D1 (de) Somatostatin analoge und deren verwendung zur behandlung von krebs
TH62586A (th) เพพไทด์สำหรับการรักษามะเร็งที่เกี่ยวข้องกับแพพิลโลมาไวรัส (hpv) ของมนุษย์และเนื้องอกของเนื้อเยื่อบุผิวอื่น
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20161122

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20171204